Polish Journal of Pathology

Abstract

3/2024 vol. 75
Original paper

The role of the CLL-1 protein in disease monitoring in patients diagnosed with acute myeloid leukaemia and myelodysplastic syndrome

Ewa Dobak 1
,
Sylwia Romana Jankowska-Szabłowska 1
,
Renata Guzicka-Kazimierczak 2
,
Paulina Poter 3
,
Elżbieta Urasińska 1
,
Katarzyna Karpińska-Łukaszewicz 1
  1. Department of Pathology, Pomeranian Medical University, Szczecin, Poland
  2. Department of Haematology and Transplantology, Pomeranian Medical University, Szczecin, Poland
  3. Department of Tumour Pathology, Greater Poland Cancer Centre, Poznań, Poland
Pol J Pathol 2024; 75 (3):182-191
DOI: https://doi.org/10.5114/pjp.2024.143228
Online publish date: 2024/10/16
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
The normal subpopulation of CD34+CD38 – haematopoietic stem cells does not express CLL-1; therefore, the assessment of the expression of this protein can be used for the diagnosis of minimal residual disease. The aim of this study was to evaluate, using multi-colour flow cytometry, the level of CLL-1 protein expression on CD34+CD38- myeloid niche cells in acute myeloid leukaemia (AML) and myelodysplastic syndromepatients at the time of diagnosis and during disease monitoring on the example of 3 practical cases. The following conclusion was drawn: CD34+CD38-CLL-1+ cells in AML patients may serve as a biomarker to predict disease aggressiveness.

Keywords

AML, CLL-1, MDS, multi-colour flow cytometry

Share
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications